[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polyneuropathies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polyneuropathies":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,52,107,144,176,204,238,275,301,322,345],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100559420","phase-3-acoramidis-transthyretin-amyloidosis-prevention-trial-in-the-young-act-early-study-in-asymptomatic-carriers-of-a-pathogenic-ttr-variant-100559420",false,"NCT06563895","Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant","A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)","Key Inclusion Criteria:\n\n* Male or female ≥ 18 to ≤ 75 years of age inclusive.\n* Participants must have an established genotype (hetero- or homozygosity) through a medically-indicated genetic test of a TTR gene variant that is known to be pathogenic or likely pathogenic (eg, V30M\u002Fp.V50M, V122I\u002Fp.V142I, T60A\u002Fp.T80A, or all other pathogenic TTR variants).\n* Participant's age is within 10 years younger than or older than PADO.\n\nKey Exclusion Criteria:\n\n* Evidence of ATTR-CM or ATTR-PN.\n* Current or past (within last 1 to 12 months, depending on specific agent) treatment with other TTR modifying therapies.\n* Contraindication to or inability to undergo cardiac magnetic resonance testing.\n* Major organ dysfunction, including: kidney disease, liver disease, heart disease (including cardiomyopathy), neuropathy\n* Other diseases or conditions such has cancer within 5 years, untreated hyperthyroidism or hypothyroidism, type 1 diabetes, active hepatitis B or C, HIV.\n* Major surgery within the past 3 months or planned during the next 12 months.\n* Known hypersensitivity to acoramidis.","ALL","18 Years","75 Years",{"count":20,"type":21},587,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age.\n\nAmyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN.\n\nAcoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs.\n\nThis study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.",[27,28,29,30,31,32],"Amyloidosis","Amyloid Cardiomyopathy","Transthyretin Amyloidosis","Cardiomyopathies","Heart Diseases","Polyneuropathies",[27,34,35,36,37,38],"ATTR-CM","ATTR-PN","Transthyretin","Amyloid","TTR","RECRUITING","2026-06-25",{"date":42,"type":43},"2026-06-29","ACTUAL",{"date":45,"type":43},"2025-05-12",{"date":47,"type":21},"2032-12",{"name":49,"class":50},"Eidos Therapeutics, a BridgeBio company","INDUSTRY",103,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":83,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100567749","phase-3-a-phase-3-study-of-ntla-2001-in-attrv-pn-100567749","NCT06672237","A Phase 3 Study of NTLA-2001 in ATTRv-PN","MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)","Inclusion Criteria:\n\n* Diagnosis of ATTRv-PN\n* Karnofsky Performance Status (KPS) ≥ 60\n\nExclusion Criteria:\n\n* Other causes of amyloidosis (amyloidosis caused by non-TTR protein)\n* Other known causes of sensorimotor or autonomic neuropathy\n* Diabetes mellitus\n* New York Heart Association Class III or IV heart failure\n* Liver failure\n* Hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection\n* Prior receipt of a TTR silencer (Small interfering RNA (siRNA) or Antisense oligonucleotides (ASOs))\n* Estimated Glomerular Filtration Rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Unable or unwilling to take vitamin A supplementation for the duration of the study\n* History of liver disease","85 Years",{"count":61,"type":21},60,[24],"This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.",[65,66,67,68,69,70,71,72,73,74,75,76,27,32,77,78,79,80,81,82],"Neuromuscular Disease","Neuromuscular Diseases (NMD)","Neurodegenerative Disease","Neurodegenerative Disease, Hereditary","Neurodegenerative Diseases","Neuromuscular Diseases","Nerve Disorders","Nervous System Disease","Nervous System Diseases","Genetic Disease, Inborn","Amyloidosis, Familial","Amyloidosis, Hereditary","Amyloid Neuropathies","Amyloid Neuropathies, Familial","Peripheral Nervous System Disease","Peripheral Nervous System Diseases","Metabolism, Inborn Errors","Metabolic Diseases",[38,27,84,85,86,35,87,36,88,89,90,91,92,93,94,95,96],"Polyneuropathy","NTLA-2001","ATTR","ATTRv-PN","TTR-mediated amyloidosis","Amyloidosis, hereditary","Amyloidosis, hereditary, transthyretin-related amyloidosis","Transthretin amyloid polyneuropathy","TTR PN","TTR polyneuropathy","nexiguran ziclumeran","nex-z","CRISPR","2026-04-13",{"date":99,"type":43},"2026-04-16",{"date":101,"type":43},"2024-11-22",{"date":103,"type":21},"2028-08",{"name":105,"class":50},"Intellia Therapeutics",14,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":119,"conditions":120,"keywords":126,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":143},"100632615","accuracy-of-the-polymerase-chain-reaction-of-ulnar-perineural-subcutaneous-aspirate-guided-by-ultrasound-for-the-diagnosis-and-monitoring-of-leprosy-cure-100632615","NCT07515989","Accuracy of the Polymerase Chain Reaction of Ulnar Perineural Subcutaneous Aspirate Guided by Ultrasound for the Diagnosis and Monitoring of Leprosy Cure","Does not exist","Inclusion Criteria:\n\nIndividuals aged 14 years or older;\n\nClinical suspicion of leprosy based on dermatologic or neurologic examination OR;\n\nPresence of peripheral nerve enlargement or skin lesions compatible with leprosy;\n\nAbility to provide written informed consent.\n\n\\-\n\nExclusion Criteria:\n\nPrevious treatment for leprosy;\n\nContraindication to the aspiration procedure (e.g., coagulopathy or anticoagulant therapy);\n\nLocal infection at the puncture site;\n\nInability or unwillingness to provide informed consent.","14 Years",{"count":116,"type":21},108,[118],"NA","\\*\\*Brief Summary\\*\\*\n\nLeprosy is a chronic granulomatous infectious disease caused by \\*Mycobacterium leprae\\* or \\*Mycobacterium lepromatosis\\*, characterized by peripheral nerve involvement that may lead to progressive neurological damage, disability, and deformities if not diagnosed and treated early. The diagnosis of leprosy is primarily clinical and epidemiological, supported by laboratory methods such as bacilloscopy and biopsy; however, these tests have limited sensitivity, particularly due to the bacillus' tropism for peripheral nerve structures.\n\nUltrasonography has emerged as a non-invasive imaging method capable of detecting morphological changes in peripheral nerves, including nerve enlargement, fascicular abnormalities, and inflammatory hypervascularization. Despite its diagnostic value, ultrasonography alone cannot detect the presence of the bacillus.\n\nThis prospective cohort study aims to evaluate the diagnostic and prognostic accuracy of combining clinical evaluation, peripheral nerve ultrasonography, and molecular detection techniques using subcutaneous perineural aspirate. Patients with suspected leprosy attending the Leprosy Outpatient Clinic at the University Hospital of Brasília will undergo clinical evaluation, ultrasound examination of the ulnar nerves, and ultrasound-guided subcutaneous perineural aspirate for molecular detection of \\*Mycobacterium leprae\\* DNA and RNA using real-time PCR and RT-PCR.\n\nParticipants will be followed for one year, with assessments performed at diagnosis and after one year of treatment. The study will compare clinical, imaging, and molecular findings to determine whether perineural subcutaneous aspirate combined with ultrasonography improves early detection and diagnostic accuracy compared with conventional methods such as bacilloscopy and biopsy.\n\nThe study aims to contribute to improved diagnostic strategies for leprosy, enabling earlier detection of neural involvement and potentially reducing disease transmission and long-term disability.",[121,122,123,124,125,32],"Leprosy","Leprosy Neuropathy","Leprosy, Multibacillary","Leprosy--Patients","Mononeuropathies",[121,127,128,129,130,131,132],"Slit Skin smear","Polimerase chain reaction","RLEP","16S","Sod","Periferal Nerve Ultrassound","2026-04-02",{"date":135,"type":43},"2026-04-07",{"date":137,"type":43},"2026-01-01",{"date":139,"type":21},"2027-08-31",{"name":141,"class":142},"University of Brasilia","OTHER",1,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":151,"targetDuration":153,"studyType":154,"phases":4,"briefSummary":155,"conditions":156,"keywords":161,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":175},"100605729","ultrasound-evaluation-of-hematoma-risk-after-needle-emg-in-patient-on-doac-therapy-100605729","NCT07166302","Ultrasound Evaluation of Hematoma Risk After Needle EMG in Patient on DOAC Therapy","U-HAND","Inclusion Criteria:\n\n* Subjects must understand the nature of the study and must provide signed and dated written informed consent prior to conducting any study-related procedures\n* Willing and able to comply with all protocol procedures\n* subjects confirmed the daily (and recent) intake od direct anticoagulants in strandard dosing.\n* no other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is taken.\n\nExclusion Criteria:\n\n* Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the investigator, would interfere with the subject's ability to participate in the study or increase the risk of participation for that subject\n* other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is recently taken.",{"count":152,"type":21},70,"7 Days","OBSERVATIONAL","Approximately 30 minutes after needle EMG, patients who are taking direct oral anticoagulants (DOACs) will undergo an ultrasound examination to evaluate for the presence of possible intramuscular hematomas at the muscles where the EMG needle was inserted. These hematomas are considered a potential adverse effect of needle EMG.\n\nThe aim of the study is to determine whether needle EMG can be considered a safe procedure in this group of patients, without posing a risk of intramuscular hematoma formation.",[157,158,159,160,125,32,66],"Direct Acting Anticoagulant Adverse Reaction","Needle Injury","EMG","Peripheral Neuropathies",[162,163,164,165],"electromyography","hematoma","ultrasonography","anticoagulants","2025-09-03",{"date":168,"type":43},"2025-09-10",{"date":170,"type":21},"2025-09",{"date":172,"type":21},"2026-12-31",{"name":174,"class":142},"Masaryk University",2,{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":193,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":4},"100601897","phase-3-to-evaluate-the-long-term-safety-and-tolerability-of-acoramidis-in-participants-with-newly-diagnosed-attr-cm-act-early-ole-100601897","NCT07116473","To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)","A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)","Key Inclusion Criteria:\n\nParticipants must have completed the AG10-501 study (ACT-EARLY study) within the past 60 calendar days with a diagnosis of ATTR-CM (based on the AG10-501 protocol definition of ATTR-CM).\n\nKey Exclusion Criteria:\n\n1. Participants who completed the AG10-501 study with a diagnosis of ATTR-PN only, or who permanently discontinued study drug prior to diagnosis of ATTR-CM in AG10-501.\n2. History of AL or another non-TTR amyloid subtype (eg, ApoA-1, gelsolin).\n3. History of a monoclonal paraprotein or abnormal light chains in serum or urine (i.e., MGUS) in which AL has not been ruled out.\n4. Stage IV or V chronic kidney disease (corresponding to an eGFR ≤ 29 mL\u002Fmin\u002F1.73 m2), or undergoing renal dialysis, or recipient of a kidney transplant.\n5. Active malignancy, except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix that has been successfully treated. In the event a participant developed a low-grade and treatable malignancy in the AG10-501 study (eg, low-grade, localized prostate cancer) and the decision by the Investigator at that time was to continue the participant in the AG10-501 study, that participant may still qualify for Study AG10-504 after documentation with the Medical Monitor.\n6. History of any organ transplant (with the exception of corneal transplant).\n7. Known hypersensitivity to acoramidis or any of the excipients within the study drug.\n8. Treatment for ATTR-CM with any ATTR-oriented on- or off-label or OTC product.",{"count":184,"type":21},250,[24],"The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).",[188,75,28,189,190,191,30,192,32,27],"Amyloidosis in Transthyretin (TTR)","Amyloid Cardiomyopathy, Transthyretin-Related","Amyloidogenic Transthyretin (ATTR) Amyloidosis","Heart Disease","Amyloidosis, Hereditary, Transthyretin-Related",[34,35,27,36,37,38,194],"Hereditary","NOT_YET_RECRUITING","2025-08-07",{"date":198,"type":43},"2025-08-11",{"date":200,"type":21},"2025-11",{"date":202,"type":21},"2037-12",{"name":49,"class":50},{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":213,"briefSummary":214,"conditions":215,"keywords":225,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":143},"100545064","using-the-ehr-to-advance-genomic-medicine-across-a-diverse-health-system-100545064","NCT06377033","Using the EHR to Advance Genomic Medicine Across a Diverse Health System","Using Behavioral Economics and Implementation Science to Advance the Use of Genomic Medicine Utilizing an EHR Infrastructure Across a Diverse Health System","Inclusion Criteria:\n\n* 18 years of age or older\n* diagnosed with one of the study conditions\n\nExclusion Criteria:\n\n* Under 18 years of age\n* not diagnosed with one of the study conditions",{"count":212,"type":21},1000,[118],"Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation and sustainable. The investigators propose an entirely new approach for the implementation of genomic medicine, supported by the leadership of Penn Medicine, investigating the use of non-geneticist clinician and patient nudges in the delivery of genomic medicine through a pragmatic randomized clinical trial, addressing NHGRI priorities. Our application is highly conceptually and technically innovative, building upon expertise and infrastructure already in place.\n\nInnovative qualities of our proposal include: 1) Cutting edge EHR infrastructure already built to support genomic medicine (e.g., partnering with multiple commercial genetic testing laboratories for direct test ordering and results reporting in the EHR); 2) Automated EHR-based direct ordering or referring by specialist clinicians (i.e., use of replicable modules that enable specialist clinicians to order genetic testing through Epic Smartsets, including all needed components, such as populated gene lists, smartphrases, genetic testing, informational websites and acknowledgement e-forms for patient signature); 3) EHR algorithms for accurate patient identification (i.e., electronic phenotype algorithms to identify eligible patients, none of which currently have phenotype algorithms present in PheKB; 4) Behavioral economics-informed implementation science methods: This trial will be the first to evaluate implementation strategies informed by behavioral economics, directed at clinicians and\u002For patients, for increasing the use of genetic testing; further it will be the first study in this area to test two forms of defaults as a potential local adaptation to facilitate implementation (ordering vs. referring); and 5) Dissemination: In addition to standard dissemination modalities,PheKB95, GitHub and Epic Community Library, the investigators propose to disseminate via AnVIL (NHGRI's Genomic Data Science Analysis, Visualization, and Informatics Lab-Space). Our results will represent an entirely new paradigm for the provision of genomic medicine for patients in whom the results of genetic testing change medical management.",[216,217,218,219,220,32,221,222,223,224],"Genetic Predisposition","Paraganglioma","Pheochromocytoma","ALS","Parkinson Disease","Frontotemporal Dementia","Alzheimer Disease","Cardiomyopathy Non-ischemic","Thoracic Aortic Aneurysm",[226,227,228],"Genetic testing","Genomic medicine","Electronic health record","2025-07-16",{"date":231,"type":43},"2025-07-20",{"date":233,"type":43},"2024-06-10",{"date":235,"type":21},"2027-06-30",{"name":237,"class":142},"University of Pennsylvania",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":245,"sex":16,"minAge":17,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":249,"conditions":250,"keywords":259,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":273,"locationsCount":143},"100519209","polyneuropathy-impairments-and-physical-activity---the-polyimpact-study-100519209","NCT06040567","Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study","PolyImPAct","Inclusion Criteria:\n\nInclusion Criteria patients:\n\n\\> 18 years Diagnosed with polyneuropathy (verified by nerve conduction)\n\nInclusion Criteria healthy controls:\n\n\\> 18 years Healthy\n\nExclusion Criteria:\n\nExclusion Criteria patients:\n\nNot verified polyneuropathy\n\nExclusion Criteria healthy controls:\n\nDiabetes, brain-, nerve-, muscle-, kidney-, or liver disease. Diagnosed with polyneuropathy",true,"100 Years",{"count":248,"type":21},520,"The project aims to investigate the validity, and reliability of outcome measures of muscle strength, functioning (gait, balance, and fine motor skills), physical activity, and patient-reported outcome measures of functioning (gait, balance, and fine motor skills), and daily living among patients with polyneuropathy. Further, the project aims to compare physical activity and patient-reported outcome measures of functioning (gait, balance, and fine motor skills), and daily living among patients with polyneuropathy with physical activity and patient-reported outcome measures of functioning (gait, balance, and fine motor skills) and daily living in healthy adults.",[251,252,253,254,255,256,257,258,32],"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Vasculitic Neuropathy","POEMS Syndrome","Multifocal Motor Neuropathy","Charcot-Marie-Tooth","hATTR Amyloidosis","Diabetic Polyneuropathy","Idiopathic Neuropathy",[84,260,261,262,263,264,265,266],"Clinical outcome measures","Patient reported outcome measures (PROMs)","Physical activity","Accelerometer","Validity","Reliability","Responsiveness","2025-04-03",{"date":269,"type":43},"2025-04-06",{"date":271,"type":43},"2023-09-23",{"date":172,"type":21},{"name":274,"class":142},"Rigshospitalet, Denmark",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":245,"sex":16,"minAge":17,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":285,"conditions":286,"keywords":287,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":175},"100574108","diagnostic-feasibility-of-100-hz-tetanic-stimulation-100574108","NCT06754995","Diagnostic Feasibility of 100 Hz Tetanic Stimulation","Diagnostic Feasibility of 100 Hz Tetanic Stimulation in the Perioperative Setting in Patients With Normal and Abnormal ENG: a Pilot Study","Inclusion Criteria:\n\n* ASA 1-3;\n* BMI 18.5-25 (normal body weight);\n* patient is in supine position with one arm accessible.\n\nExclusion Criteria:\n\n* diseases with impaired neuromuscular function (myopathies, severe liver and kidney failure);\n* drugs affecting neuromuscular function (magnesium, aminoglycosides);\n* pregnancy (pregnancy tests are carried out in women of childbearing age to rule out pregnancy);\n* breast-feeding;\n* acute surgery","65 Years",{"count":284,"type":21},40,"The goal of this observational study is to investigate the applicability of 100 Hz tetanic stimulation with an electromyography device in the exclusion of postoperative residual neuromuscular block. The aim is to determine whether fatigue develops with 100 Hz tetanic stimulation in anaesthetized, non-relaxed patients with normal or abnormal baseline electroneurographic (ENG) findings.",[32],[162,288,289,290,291],"electroneurography","tetanic stimulation","residual neuromuscular block","neuromuscular monitoring","2025-03-26",{"date":294,"type":43},"2025-03-27",{"date":296,"type":43},"2025-01-06",{"date":298,"type":21},"2027-12-31",{"name":300,"class":142},"University of Debrecen",{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":308,"enrollmentInfo":309,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":4},"100546099","ultrasonography-in-diagnosis-of-polyneuropathy-100546099","NCT06390527","Ultrasonography in Diagnosis of Polyneuropathy","Optimization of Ultrasound Sheer Wave Elastography for the Evaluation of Peripheral Nerve Disorders","Inclusion Criteria:\n\n* Age 18-80 years\n* Clinical signs of particular polyneuropathy not explained by other causes\n\nExclusion Criteria:\n\n* Entrapment or compression neuropathies\n* Nerve trauma\n* The diagnosis of vasculitic neuropathy, neuralgic amyotrophy, diabetic radiculo-plexo-neuropathy, hereditary neuropathy with liability to pressure palsies and motor neuron disorders including monomelic amyotrophy.","80 Years",{"count":310,"type":21},120,"The main goal of this trial is to establish recommendations for clinical practice that enhance the reliability, accessibility and convenience of sheer wave elastography as a routine diagnostic test for diverse peripheral neuropathies.",[32],"2024-04-25",{"date":315,"type":43},"2024-04-30",{"date":317,"type":21},"2024-06-01",{"date":319,"type":21},"2027-02-01",{"name":321,"class":142},"University Medical Centre Ljubljana",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":331,"conditions":332,"keywords":333,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":143},"100519524","prognostic-value-of-biomarkers-in-polyneuropathy-100519524","NCT06044662","Prognostic Value of Biomarkers in Polyneuropathy.","The Prognostic Value of Blood Biomarkers for Patients With Polyneuropathy.","Inclusion Criteria:\n\n* Minimum 18 years old.\n* Diagnosed with polyneuropathy, confirmed by nerve conduction study.\n* Can read and understand Danish.\n\nExclusion Criteria:\n\n* Inability to perform physical tests due to comorbidity not associated to the patient's polyneuropathy.",{"count":330,"type":21},200,"Biomarkers for prognosis of patients with polyneuropathy.",[32],[334,335,336],"polyneuropathy","biomarkers","cohort study","2024-04-09",{"date":339,"type":43},"2024-04-11",{"date":341,"type":43},"2023-10-27",{"date":343,"type":21},"2026-10",{"name":274,"class":142},{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":352,"enrollmentInfo":353,"targetDuration":355,"studyType":154,"phases":4,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":368,"locationsCount":370},"100351938","exploring-the-genetics-of-neuropathic-pain-100351938","NCT03862365","Exploring the Genetics of Neuropathic Pain","GeNeup","Inclusion Criteria:\n\n1. The patient is between 18 and 70 years old.\n2. The patient has consented.\n3. The patient is referred for evaluation of possible distal symmetric polyneuropathy (DSPN).\n4. The patient has filled out the questionnaires.\n\nExclusion Criteria:\n\n1. The patient is too sick to participate (eg. bedridden, fever).\n2. The patient is unable to consent (eg. dementia, speech problems, psychiatric disorder).\n3. Inflammatory acute polyneuropathy.","70 Years",{"count":354,"type":21},5000,"1 Day","In the present study the investigators will search for new genetic variants relevant for the development of neuropathic pain.",[358,216,32],"Neuropathic Pain",[360,361],"reliability","validity","2023-11-06",{"date":364,"type":43},"2023-11-07",{"date":366,"type":43},"2018-08-01",{"date":298,"type":21},{"name":369,"class":142},"Oslo University Hospital",5]